Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Christopher W. Reynolds joins Ethics Talk to discuss his article, coauthored with Camilo Sánchez Meertens: “How Should Health Systems Help Clinicians Manage Bias Against Ex-combatants?”
This article considers 1990s and 2000s-era civil rights complaints in NYC and offers legal strategies for scaling health outcomes improvement nationwide.
AMA J Ethics. 2023;25(1):E48-54. doi:
10.1001/amajethics.2023.48.